- BS, Biomedical Engineering, Drexel University, 2007
- PhD, Cell and Developmental Biology, Sidney Kimmel Medical College of Thomas Jefferson University, 2016
- MD, Sidney Kimmel Medical College of Thomas Jefferson University, 2016
- Residency, Internal Medicine, University of Pittsburgh Medical Center, 2018
- Fellowship, Hematology/Medical Oncology, University of Pittsburgh Medical Center, 2021
- Post-Doctoral Fellowship, University of Pittsburgh School of Medicine, 2023
Education & Training
Quann K, Sacirbegovic F, Rosenberger S, McFerran ER, Codispot KC, Garcia-Dieguez L, Rowe AM, Wei W, Jain D, McNiff JM, Shlomchik W. The role of TCF-1+CD8+ exhausted progenitors and TCF-1 in graft-versus-host responses. JCI Insight. 2025 Oct 8;10(19). PMID: 41059570.
Neupane B, Ventura K, Parr K, Lee JR, Quann K, Chen C, Barrett AJ, Ito S. Dynamics of neoantigen-specific T-cells in post-transplant relapse: do leukemia neoantigens elicit immune responses in transplant recipients?. Bone Marrow Transplant. 2025 Apr;60(4):541-545. PMID: 39881205.
Quann K, Lontos K, Sehgal A, Raptis A, Im A, Redner RL, Dorritie KA, Agha M, Hou JZ, Farah R, Rossetti J, Normolle DP, Whiteside TL, Hsu YS, Boyiadzis M. A phase II study of post-remission therapy with pembrolizumab in older patients with acute myeloid leukemia. Haematologica. 2024 Dec 1;109(12):4106-4111. PMID: 39113675.
Im A, Quann K, Agha M, Raptis A, Redner RL, Hou JZ, Farah R, Dorritie KA, Sehgal AR, Normolle D, Bovbjerg DH, Aggarwal N, Herman J, Lontos K, Boyiadzis M. Phase 2 study of epigenetic priming with decitabine followed by cytarabine for acute myeloid leukemia in older patients. Am J Hematol. 2024 Mar;99(3):380-386. PMID: 38258329.
Quann K, Sacirbegovic F, Shlomchik WD. Natalizumab for GVHD: too little or too late?. Blood Adv. 2023 Sep 12;7(17):5187-5188. PMID: 37698891.
Allogeneic hematopoietic stem cell transplantation (alloSCT) is a powerful form of immunotherapy in which donor T cells can recognize non-self antigens expressed by recipient hematopoietic cells to promote a graft-vs-leukemia (GVL) effect. Conversely, donor T cells also recognize non-self antigens expressed by healthy recipient tissues, leading to pathological graft-vs-host disease. The specific antigens contributing to GVL and/or GVHD remain largely unknown despite decades of experience with alloSCT. My research interests lie in identifying and characterizing these antigenic determinants of alloimmunity, with the goal of developing strategies for mitigating GVHD while preserving or enhancing GVL in alloSCT.
